Then, the dose might change based on how you react and other factors
Particularly important for those on acid-blocking medications, metformin, vegetarians, or patients with gastritis
Putting the evidence side by side Here is the blunt comparison: AOD 9604: 2.6 kg weight loss in 12 weeks (best result), failed six clinical trials, development terminated Semaglutide: 15 to 17 percent body weight loss over 68 weeks, FDA approved, thousands of study participants, consistent results across multiple trials There is no way to frame this comparison that puts AOD 9604 on equal footing with semaglutide when it comes to clinical evidence
In short: BPC-157 appears safe when used responsibly, but due diligence with dosing, sourcing, and timing is essentialespecially when addressing complex GI disorders